Clinical trial · no report yet · Phase 3
MIDAS
MInimal Residual Disease Adapted Strategy
- NCT04934475 ↗
- Active, not recruiting
- Intergroupe Francophone du Myelome
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 75 | |
| X threads | 69 | |
| Podcasts | 33 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- MInimal Residual Disease Adapted Strategy: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation Less Than 66 Years; a Prospective Study
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Isatuximab; ASCT
- Arms
- MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization) : Arm A · Experimental
- MRD Standard-risk patients (post induction MRD <10-5, MRD SR) (1:1 Randomization): Arm B · Experimental
- MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm C · Experimental
- MRD High-risk patients (post induction MRD >10-5, MRD HR) (1:1 Randomization): Arm D · Experimental
- Enrollment
- 791
- Primary outcomes
- Negative MRD rate
- Negative MRD rate
- Negative MRD rate
- Negative MRD rate
- Sponsor
- Intergroupe Francophone du Myelome with Amgen, Sanofi, Bristol-Myers Squibb
- Start
- Dec 8, 2021
- Primary completion
- Sep 30, 2024
- Results posted
- No
- Registry record
- NCT04934475 · updated Nov 7, 2024
Publications
linked from the registry- Magrangeas F, Cherkaoui M, Bessonneau-Gaborit V, Derrien J, Chevalier C, Guerin-Charbonnel C, Diamond B, Samur MK; Intergroupe Francophone du Myelome (IFM); Hulin C, Caillot D, Karlin L, Arnulf B, Landgren O, Munshi NC, Avet-Loiseau H, Martinet L, Corre J, Perrot A, Moreau P, Touzeau C, Minvielle S, Letouze E. Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy. Nat Med. 2026 Oct 19. doi: 10.1038/s41591-026-04692-0. Online ahead of print. PubMed 42897348
- Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre-Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Mohty M, Leleu X, Manier S, Mariette C, Chaleteix C, Braun T, De Prijck B, Avet-Loiseau H, Mary JY, Corre J, Moreau P, Touzeau C; MIDAS Study Group. Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma. N Engl J Med. 2025 Jul 31;393(5):425-437. doi: 10.1056/NEJMoa2505133. Epub 2025 Jun 3. PubMed 40459097
- Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Tiab M, Mohty M, Kuhnowski F, Fontan J, Manier S, Orsini-Piocelle F, Vincent L, Rigaudeau S, Leleu X, Hebraud B, Flet L, Malfuson JV, Jacquet C, Chaoui D, Meuleman N, Abarah W, Montes L, Benramdane R, Sonntag C, Zerazhi H, Danu A, Allangba O, Dib M, Roussel M, Cereja S, Depaus J, Branche N, Demarquette H, Richez V, Cherel B, Frenzel L, Vekemans MC, Bigot N, Avet-Loiseau H, Corre J, Moreau P. Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial. Blood. 2025 Jul 3;146(1):52-61. doi: 10.1182/blood.2024026230. PubMed 39841461
- Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 Jun 1;97(6):E195-E198. doi: 10.1002/ajh.26530. Epub 2022 Mar 21. No abstract available. PubMed 35285981